Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Study Overview
=================
Brief Summary
-----------------
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Detailed Description
-----------------
The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Official Title
-----------------
Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial

Conditions
-----------------
Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression

Intervention / Treatment
-----------------
* Procedure: Intracameral injection
* Procedure: Intravitreal injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of neovascular glaucoma The patients having IOP > 21 mmHg, having the indication for trabeculectomy The patients' age of at least 18-year-old The patients having visual potential at least hand motion. Present of NVI or NVA. Willing and able to provide informed consent to participate in the study Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits Exclusion Criteria: One eye patient Patients having severe corneal edema or total hyphema obscure NVI or NVA view. Cannot obtain endothelial cell count. History of bevacizumab or fluorescence dye allergy. Active infectious ocular disease including endophthalmitis and corneal ulcer History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension Has or planning to be pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intracameral injection<br>Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection | Procedure: Intracameral injection<br>* A/C injection of 1.25 mg/0.05 mL bevacizumab<br>|
| Experimental: Intravitreal injection<br>Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection | Procedure: Intravitreal injection<br>* Vitreous injection of 1.25 mg/0.05 mL bevacizumab<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| regression of nevolascularization | Amount of nevolascular of iris and angle regression | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP reduction | IOP reduction at 2-month visit compare to baseline | 2 months | 
| Injection complication | Hyphema, IOP spike | 2 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neovascular glaucoma